SLC18A2 (solute carrier family 18 member A2)

2007-11-01  

Identity

HGNC
LOCATION
10q25.3
LOCUSID
ALIAS
PKDYS2,SVAT,SVMT,VAT2,VMAT2

Other Information

Locus ID:

NCBI: 6571
MIM: 193001
HGNC: 10935
Ensembl: ENSG00000165646

Variants:

dbSNP: 6571
ClinVar: 6571
TCGA: ENSG00000165646
COSMIC: SLC18A2

RNA/Proteins

Gene IDTranscript IDUniprot
ENSG00000165646ENST00000644641Q05940

Expression (GTEx)

0
1
2
3
4
5
6
7
8

Pathways

PathwaySourceExternal ID
Parkinson's diseaseKEGGhsa05012
Synaptic vesicle cycleKEGGko04721
Synaptic vesicle cycleKEGGhsa04721
Dopaminergic synapseKEGGko04728
Dopaminergic synapseKEGGhsa04728
Serotonergic synapseKEGGhsa04726
Cocaine addictionKEGGhsa05030
Cocaine addictionKEGGko05030
Amphetamine addictionKEGGhsa05031
Amphetamine addictionKEGGko05031
AlcoholismKEGGhsa05034
AlcoholismKEGGko05034
Neuronal SystemREACTOMER-HSA-112316
Transmission across Chemical SynapsesREACTOMER-HSA-112315
Neurotransmitter Release CycleREACTOMER-HSA-112310
Norepinephrine Neurotransmitter Release CycleREACTOMER-HSA-181430
Serotonin Neurotransmitter Release CycleREACTOMER-HSA-181429
Dopamine Neurotransmitter Release CycleREACTOMER-HSA-212676
Transmembrane transport of small moleculesREACTOMER-HSA-382551
SLC-mediated transmembrane transportREACTOMER-HSA-425407
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compoundsREACTOMER-HSA-425366
Na+/Cl- dependent neurotransmitter transportersREACTOMER-HSA-442660

Protein levels (Protein atlas)

Not detected
Low
Medium
High

PharmGKB

Entity IDNameTypeEvidenceAssociationPKPDPMIDs
PA447215Psychotic DisordersDiseaseClinicalAnnotationassociatedPD27272046
PA447321Depressive Disorder, MajorDiseaseClinicalAnnotationassociatedPD22947179
PA448687bupropionChemicalClinicalAnnotationassociatedPD22947179
PA452233antipsychoticsChemicalClinicalAnnotationassociatedPD27272046

References

Pubmed IDYearTitleCitations
380812992024Transport and inhibition mechanisms of human VMAT2.4
381638462024Transport and inhibition mechanism for VMAT2-mediated synaptic vesicle loading of monoamines.5
380812992024Transport and inhibition mechanisms of human VMAT2.4
381638462024Transport and inhibition mechanism for VMAT2-mediated synaptic vesicle loading of monoamines.5
363182702023Brain monoamine vesicular transport disease caused by homozygous SLC18A2 variants: A study in 42 affected individuals.8
363182702023Brain monoamine vesicular transport disease caused by homozygous SLC18A2 variants: A study in 42 affected individuals.8
347746562022Comparisons of vesicular monoamine transporter type 2 signals in Parkinson's disease and parkinsonism secondary to carbon monoxide poisoning.1
355247722022Sclerosing Paragangliomas: Correlations of Histological Features with Patients' Genotype and Vesicular Monoamine Transporter Expression.0
347746562022Comparisons of vesicular monoamine transporter type 2 signals in Parkinson's disease and parkinsonism secondary to carbon monoxide poisoning.1
355247722022Sclerosing Paragangliomas: Correlations of Histological Features with Patients' Genotype and Vesicular Monoamine Transporter Expression.0
347588452021VMAT2 availability in Parkinson's disease with probable REM sleep behaviour disorder.6
347588452021VMAT2 availability in Parkinson's disease with probable REM sleep behaviour disorder.6
304714182019Decreased pallidal vesicular monoamine transporter type 2 availability in Parkinson's disease: The contribution of the nigropallidal pathway.7
309835002019VMAT2 gene (SLC18A2) variants associated with a greater risk for developing opioid dependence.5
313174762019Synaptic Vesicle Protein 2 and Vesicular Monoamine Transporter 1 and 2 Are Expressed in Neuroblastoma.3

Citation

Dessen P

SLC18A2 (solute carrier family 18 member A2)

Atlas Genet Cytogenet Oncol Haematol. 2007-11-01

Online version: http://atlasgeneticsoncology.org/gene/49830/slc18a2